Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Legend Biotech Corp LEGN

Healthcare Biotechnology
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LEGN)

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

GlobeNewswire 4 days ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

GlobeNewswire February 25, 2025

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2024

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

GlobeNewswire December 9, 2024

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

GlobeNewswire November 12, 2024

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire November 7, 2024

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

GlobeNewswire November 5, 2024

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

GlobeNewswire November 4, 2024

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

GlobeNewswire October 24, 2024
View More News ››

Opinion & Analysis (NDAQ:LEGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LEGN)

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI&

Just In: $LEGN Legend Biotech Announces Positive CHMP Opinion for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the Treatment of...
whytestocks - February 23, 2024
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »